Tyra Biosciences reports interim TYRA-300 data: 54.5% confirmed PR in FGFR3+ mUC at ≥90 mg QD

Tyra Biosciences, Inc.

As of Aug 15, 2024, 41 patients enrolled in SURF301 Phase 1; 6/11 (54.5%) FGFR3+ mUC patients at ≥90 mg QD achieved confirmed partial response, 3 ongoing.
100% disease control rate (PR + stable disease) observed in patients at ≥90 mg QD.
TYRA-300 generally well-tolerated; no Gr4+ TRAEs, 1 DLT (Gr3 diarrhea) and 1 discontinuation (Gr3 ALT) at 90 mg QD.
Director Siddarth Subramony resigned from Board and Compensation Committee effective Oct 24, 2024, not due to any disagreement.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Siddarth Subramony

Director

TYRA · Tyra Biosciences, Inc.

Effective: 2024-10-24
Filed: October 25, 2024, 7:59 PM ET

On October 24, 2024, Siddarth Subramony, Ph.D. resigned from the Board of Directors (the Board) of Tyra Biosciences, Inc. (Tyra or the Company) and the Compensation Committee of the Board (the Compensation Committee) effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Siddarth Subramony resigned as Director at Tyra Biosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 24, 2024, Siddarth Subramony, Ph.D. resigned from the Board of Directors (the Board) of Tyra Biosciences, Inc. (Tyra or the Company) and the Compensation Committee of the Board (the Compensation Committee) effective immediately.

View on SEC.gov

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-243475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.